Home Newsfeeds Raymond James Maintains Outperform on Compass Therapeutics, Raises Price Target to $8

Raymond James Maintains Outperform on Compass Therapeutics, Raises Price Target to $8

Raymond James analyst Dane Leone maintains Compass Therapeutics (NASDAQ:CMPX) with a Outperform and raises the price target from $5 to $8.

byBenzinga Newsdesk

November 10, 2022

1 minute read

Raymond James analyst Dane Leone maintains Compass Therapeutics (NASDAQ:CMPX) with a Outperform and raises the price target from $5 to $8.

Jefferies Maintains Hold on Oracle, Raises Price Target to $85

By Benzinga Newsdesk

September 13, 6:51 AM

Jefferies analyst Brent Thill maintains Oracle (NYSE:ORCL) with a Hold and raises the price target from $80 to $85.

ORCL

CACI Awarded $2.7B National Security Agency Contract To Provide Intelligence Analysis

By Happy Mohamed

August 3, 8:16 AM

CACI International Inc ((CACI) announced today that it was awarded a mission expertise contract valued at up to $2.7 billion to provide network and exploitation analysis to the National Security Agency's

CACI

ICZOOM Announces Cancellation Of Proposed Public Offering; Cancellation Due To Current Market Pricing Not Conducive For Offering That Would Be In Best Interests Of Co Or Its Shareholders

By Benzinga Newsdesk

April 17, 10:56 AM

ICZOOM Group Inc. (NASDAQ:IZM) (the "Company" or "ICZOOM"), announced today that it voluntarily requested a withdrawal of a registration statement on Form F-1 filed with the U.S. Securities and Exchange Commission (File

IZM

Wedbush Maintains Neutral on BJ’s Restaurants, Raises Price Target to $25

By Benzinga Newsdesk

July 22, 6:09 AM

Wedbush analyst Nick Setyan maintains BJ's Restaurants (NASDAQ:BJRI) with a Neutral and raises the price target from $24 to $25.

BJRI

Raymond James Maintains Outperform on Compass Therapeutics, Raises Price Target to $8

Related Posts

Jefferies Maintains Hold on Oracle, Raises Price Target to $85

CACI Awarded $2.7B National Security Agency Contract To Provide Intelligence Analysis

ICZOOM Announces Cancellation Of Proposed Public Offering; Cancellation Due To Current Market Pricing Not Conducive For Offering That Would Be In Best Interests Of Co Or Its Shareholders

Wedbush Maintains Neutral on BJ’s Restaurants, Raises Price Target to $25